<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33466313</PMID><DateRevised><Year>2021</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>Inhibition of Type III Interferon Expression in Intestinal Epithelial Cells-A Strategy Used by Coxsackie B Virus to Evade the Host's Innate Immune Response at the Primary Site of Infection?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">105</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms9010105</ELocationID><Abstract><AbstractText>Increasing evidence highlights the importance of the antiviral activities of the type III interferons (IFN&#x3bb;s; IL-28A, IL-28B, IL29, and IFN&#x3bb;4) in the intestine. However, many viruses have developed strategies to counteract these defense mechanisms by preventing the production of IFNs. Here we use infection models, a clinical virus isolate, and several molecular biology techniques to demonstrate that both type I and III IFNs induce an antiviral state and attenuate Coxsackievirus group B (CVB) replication in human intestinal epithelial cells (IECs). While treatment of IECs with a viral mimic (poly (I:C)) induced a robust expression of both type I and III IFNs, no such up-regulation was observed after CVB infection. The blunted IFN response was paralleled by a reduction in the abundance of proteins involved in the induction of interferon gene transcription, including TIR-domain-containing adapter-inducing interferon-&#x3b2; (TRIF), mitochondrial antiviral-signaling protein (MAVS), and the global protein translation initiator eukaryotic translation initiation factor 4G (eIF4G). Taken together, this study highlights a potent anti-Coxsackieviral effect of both type I and III IFNs in cells located at the primary site of infection. Furthermore, we show for the first time that the production of type I and III IFNs in IECs is blocked by CVBs. These findings suggest that CVBs evade the host immune response in order to successfully infect the intestine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Virginia M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringqvist</LastName><ForeName>Emma E</ForeName><Initials>EE</Initials><Identifier Source="ORCID">0000-0001-6303-6076</Identifier><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>P&#xe4;r G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domsgen</LastName><ForeName>Erna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmlund</LastName><ForeName>Ulrika</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Education and Innovation, Karolinska University Hospital, 171 64 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sverremark-Ekstr&#xf6;m</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flodstr&#xf6;m-Tullberg</LastName><ForeName>Malin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2685-2052</Identifier><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>260441/PEVNET</GrantID><Agency>FP7 Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus (CVB)</Keyword><Keyword MajorTopicYN="N">IFIH1</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">immune evasion</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">intestinal epithelial cells</Keyword><Keyword MajorTopicYN="N">intestine</Keyword><Keyword MajorTopicYN="N">poly I:C</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword></KeywordList><CoiStatement>M.F.-T. serve on the scientific advisory board of Provention Bio Inc., which develops vaccines against Coxsackie B virus. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33466313</ArticleId><ArticleId IdType="pmc">PMC7824802</ArticleId><ArticleId IdType="doi">10.3390/microorganisms9010105</ArticleId><ArticleId IdType="pii">microorganisms9010105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Broggi A., Granucci F., Zanoni I. Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion. J. Exp. Med. 2020;217:e20190295. doi: 10.1084/jem.20190295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190295</ArticleId><ArticleId IdType="pmc">PMC7037241</ArticleId><ArticleId IdType="pubmed">31821443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazear H.M., Schoggins J.W., Diamond M.S. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. 2019;50:907&#x2013;923. doi: 10.1016/j.immuni.2019.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.025</ArticleId><ArticleId IdType="pmc">PMC6839410</ArticleId><ArticleId IdType="pubmed">30995506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingle H., Peterson S.T., Baldridge M.T. Distinct Effects of Type I and III Interferons on Enteric Viruses. Viruses. 2018;10:46. doi: 10.3390/v10010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10010046</ArticleId><ArticleId IdType="pmc">PMC5795459</ArticleId><ArticleId IdType="pubmed">29361691</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells A.I., Coyne C.B. Type III Interferons in Antiviral Defenses at Barrier Surfaces. Trends Immunol. 2018;39:848&#x2013;858. doi: 10.1016/j.it.2018.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2018.08.008</ArticleId><ArticleId IdType="pmc">PMC6179363</ArticleId><ArticleId IdType="pubmed">30219309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L., Schnepf D., Staeheli P. Interferon-lambda orchestrates innate and adaptive mucosal immune responses. Nat. Rev. Immunol. 2019;19:614&#x2013;625. doi: 10.1038/s41577-019-0182-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0182-z</ArticleId><ArticleId IdType="pubmed">31201377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemball C.C., Alirezaei M., Whitton J.L. Type B coxsackieviruses and their interactions with the innate and adaptive immune systems. Future Microbiol. 2010;5:1329&#x2013;1347. doi: 10.2217/fmb.10.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.10.101</ArticleId><ArticleId IdType="pmc">PMC3045535</ArticleId><ArticleId IdType="pubmed">20860480</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S.J., Morgan N.G. Enteroviral infections in the pathogenesis of type 1 diabetes: New insights for therapeutic intervention. Curr. Opin. Pharmacol. 2018;43:11&#x2013;19. doi: 10.1016/j.coph.2018.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2018.07.006</ArticleId><ArticleId IdType="pmc">PMC6294842</ArticleId><ArticleId IdType="pubmed">30064099</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanter M., Sork H., Tuomela S., Flodstrom-Tullberg M. Genetic and Environmental Interaction in Type 1 Diabetes: A relationship between genetic risk alleles and molecular traits of enterovirus infection? Curr. Diab. Rep. 2019;19:82. doi: 10.1007/s11892-019-1192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-019-1192-8</ArticleId><ArticleId IdType="pmc">PMC6689284</ArticleId><ArticleId IdType="pubmed">31401790</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind K., Huhn M.H., Flodstrom-Tullberg M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: The innate immune response to enteroviruses and its possible role in regulating type 1 diabetes. Clin. Exp. Immunol. 2012;168:30&#x2013;38. doi: 10.1111/j.1365-2249.2011.04557.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2011.04557.x</ArticleId><ArticleId IdType="pmc">PMC3390490</ArticleId><ArticleId IdType="pubmed">22385234</ArticleId></ArticleIdList></Reference><Reference><Citation>Sin J., Mangale V., Thienphrapa W., Gottlieb R.A., Feuer R. Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. Virology. 2015;484:288&#x2013;304. doi: 10.1016/j.virol.2015.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2015.06.006</ArticleId><ArticleId IdType="pmc">PMC4567421</ArticleId><ArticleId IdType="pubmed">26142496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozym R.A., Morosky S.A., Kim K.S., Cherry S., Coyne C.B. Release of intracellular calcium stores facilitates coxsackievirus entry into polarized endothelial cells. PLoS Pathog. 2010;6:e1001135. doi: 10.1371/journal.ppat.1001135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001135</ArticleId><ArticleId IdType="pmc">PMC2951373</ArticleId><ArticleId IdType="pubmed">20949071</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne C.B., Bergelson J.M. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell. 2006;124:119&#x2013;131. doi: 10.1016/j.cell.2005.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.10.035</ArticleId><ArticleId IdType="pubmed">16413486</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrath R., Bourlet T., Delezay O., Douche-Aourik F., Omar S., Aouni M., Pozzetto B. Coxsackievirus B3 replication and persistence in intestinal cells from mice infected orally and in the human CaCo-2 cell line. J. Med. Virol. 2004;74:283&#x2013;290. doi: 10.1002/jmv.20179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20179</ArticleId><ArticleId IdType="pubmed">15332278</ArticleId></ArticleIdList></Reference><Reference><Citation>Riabi S., Gaaloul I., Harrath R., Aouni M. Persistent infection of human intestinal Caco-2 cell line by Coxsackieviruses B. Pathol. Biol. 2012;60:347&#x2013;351. doi: 10.1016/j.patbio.2011.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patbio.2011.11.004</ArticleId><ArticleId IdType="pubmed">22178701</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond C.G., Bolock A.M., Ma C., Luke C.J., Good M., Coyne C.B. Enteroviruses infect human enteroids and induce antiviral signaling in a cell lineage-specific manner. Proc. Natl. Acad. Sci. USA. 2017;114:1672&#x2013;1677. doi: 10.1073/pnas.1617363114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1617363114</ArticleId><ArticleId IdType="pmc">PMC5320971</ArticleId><ArticleId IdType="pubmed">28137842</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond C.G., Nickerson C.A., Coyne C.B. A Three-Dimensional Cell Culture Model To Study Enterovirus Infection of Polarized Intestinal Epithelial Cells. mSphere. 2016;1 doi: 10.1128/mSphere.00030-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00030-15</ArticleId><ArticleId IdType="pmc">PMC4863623</ArticleId><ArticleId IdType="pubmed">27303677</ArticleId></ArticleIdList></Reference><Reference><Citation>Villenave R., Wales S.Q., Hamkins-Indik T., Papafragkou E., Weaver J.C., Ferrante T.C., Bahinski A., Elkins C.A., Kulka M., Ingber D.E. Human Gut-On-A-Chip Supports Polarized Infection of Coxsackie B1 Virus In Vitro. PLoS ONE. 2017;12:e0169412. doi: 10.1371/journal.pone.0169412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169412</ArticleId><ArticleId IdType="pmc">PMC5287454</ArticleId><ArticleId IdType="pubmed">28146569</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M., Tauriainen S., Oikarinen S., Honkanen T., Collin P., Rantala I., Maki M., Kaukinen K., Hyoty H. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes. 2012;61:687&#x2013;691. doi: 10.2337/db11-1157.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-1157</ArticleId><ArticleId IdType="pmc">PMC3282798</ArticleId><ArticleId IdType="pubmed">22315304</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstrom M., Maday A., Balakrishna D., Cleary M.M., Yoshimura A., Sarvetnick N. Target cell defense prevents the development of diabetes after viral infection. Nat. Immunol. 2002;3:373&#x2013;382. doi: 10.1038/ni771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni771</ArticleId><ArticleId IdType="pubmed">11919579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutton C.W., Gauntt C.J. Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice. J. Interferon Res. 1985;5:137&#x2013;146. doi: 10.1089/jir.1985.5.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.1985.5.137</ArticleId><ArticleId IdType="pubmed">2985716</ArticleId></ArticleIdList></Reference><Reference><Citation>Koestner W., Spanier J., Klause T., Tegtmeyer P.K., Becker J., Herder V., Borst K., Todt D., Lienenklaus S., Gerhauser I., et al. Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice. PLoS Pathog. 2018;14:e1007235. doi: 10.1371/journal.ppat.1007235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007235</ArticleId><ArticleId IdType="pmc">PMC6107283</ArticleId><ArticleId IdType="pubmed">30075026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultcrantz M., Huhn M.H., Wolf M., Olsson A., Jacobson S., Williams B.R., Korsgren O., Flodstrom-Tullberg M. Interferons induce an antiviral state in human pancreatic islet cells. Virology. 2007;367:92&#x2013;101. doi: 10.1016/j.virol.2007.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2007.05.010</ArticleId><ArticleId IdType="pubmed">17559902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind K., Richardson S.J., Leete P., Morgan N.G., Korsgren O., Flodstrom-Tullberg M. Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets. J. Virol. 2013;87:7646&#x2013;7654. doi: 10.1128/JVI.03431-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03431-12</ArticleId><ArticleId IdType="pmc">PMC3700265</ArticleId><ArticleId IdType="pubmed">23637411</ArticleId></ArticleIdList></Reference><Reference><Citation>Domsgen E., Lind K., Kong L., Huhn M.H., Rasool O., van Kuppeveld F., Korsgren O., Lahesmaa R., Flodstrom-Tullberg M. An IFIH1 gene polymorphism associated with risk for autoimmunity regulates canonical antiviral defence pathways in Coxsackievirus infected human pancreatic islets. Sci. Rep. 2016;6:39378. doi: 10.1038/srep39378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39378</ArticleId><ArticleId IdType="pmc">PMC5175199</ArticleId><ArticleId IdType="pubmed">28000722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind K., Svedin E., Utorova R., Stone V.M., Flodstrom-Tullberg M. Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection. Clin. Exp. Immunol. 2014;177:687&#x2013;695. doi: 10.1111/cei.12368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12368</ArticleId><ArticleId IdType="pmc">PMC4137853</ArticleId><ArticleId IdType="pubmed">24773058</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O.H., Svedin E., Kapell S., Nurminen A., Hytonen V.P., Flodstrom-Tullberg M. Enteroviral proteases: Structure, host interactions and pathogenicity. Rev. Med. Virol. 2016;26:251&#x2013;267. doi: 10.1002/rmv.1883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1883</ArticleId><ArticleId IdType="pmc">PMC7169145</ArticleId><ArticleId IdType="pubmed">27145174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells A.I., Coyne C.B. Enteroviruses: A Gut-Wrenching Game of Entry, Detection, and Evasion. Viruses. 2019;11:460. doi: 10.3390/v11050460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11050460</ArticleId><ArticleId IdType="pmc">PMC6563291</ArticleId><ArticleId IdType="pubmed">31117206</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser L.J., Langereis M.A., Rabouw H.H., Wahedi M., Muntjewerff E.M., de Groot R.J., van Kuppeveld F.J.M. Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule Formation and the Induction of Type I Interferon. J. Virol. 2019;93 doi: 10.1128/JVI.00222-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00222-19</ArticleId><ArticleId IdType="pmc">PMC6498061</ArticleId><ArticleId IdType="pubmed">30867299</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M., Kapell S., Hertz N.T., Wu X., Bell K., Ashbrook A.W., Mark M.T., Zebroski H.A., Neal M.L., Flodstrom-Tullberg M., et al. Defining the proteolytic landscape during enterovirus infection. PLoS Pathog. 2020;16:e1008927. doi: 10.1371/journal.ppat.1008927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008927</ArticleId><ArticleId IdType="pmc">PMC7549765</ArticleId><ArticleId IdType="pubmed">32997711</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Langereis M.A., Lork M., Nguyen M., Hato S.V., Lanke K., Emdad L., Bhoopathi P., Fisher P.B., Lloyd R.E., et al. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J. Virol. 2014;88:3369&#x2013;3378. doi: 10.1128/JVI.02712-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02712-13</ArticleId><ArticleId IdType="pmc">PMC3957915</ArticleId><ArticleId IdType="pubmed">24390337</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris K.G., Coyne C.B. Death waits for no man--does it wait for a virus? How enteroviruses induce and control cell death. Cytokine Growth Factor Rev. 2014;25:587&#x2013;596. doi: 10.1016/j.cytogfr.2014.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.08.002</ArticleId><ArticleId IdType="pmc">PMC4371850</ArticleId><ArticleId IdType="pubmed">25172372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagdeo J.M., Dufour A., Klein T., Solis N., Kleifeld O., Kizhakkedathu J., Luo H., Overall C.M., Jan E. N-Terminomics TAILS Identifies Host Cell Substrates of Poliovirus and Coxsackievirus B3 3C Proteinases That Modulate Virus Infection. J. Virol. 2018;92 doi: 10.1128/JVI.02211-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02211-17</ArticleId><ArticleId IdType="pmc">PMC5874412</ArticleId><ArticleId IdType="pubmed">29437971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind K., Svedin E., Domsgen E., Kapell S., Laitinen O.H., Moll M., Flodstrom-Tullberg M. Coxsackievirus counters the host innate immune response by blocking type III interferon expression. J. Gen. Virol. 2016;97:1368&#x2013;1380. doi: 10.1099/jgv.0.000443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000443</ArticleId><ArticleId IdType="pubmed">26935471</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O.H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M.M., Huhtala H., Ruokoranta T., Lecouturier V., Andre P., Harju R., et al. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes. 2014;63:446&#x2013;455. doi: 10.2337/db13-0619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T., Otte J.M., Diebold J., Diepolder H., Adler B., Auernhammer C.J., et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 2005;289:G960&#x2013;G968. doi: 10.1152/ajpgi.00126.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00126.2005</ArticleId><ArticleId IdType="pubmed">16051921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T.S., Fujita T., Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008;205:1601&#x2013;1610. doi: 10.1084/jem.20080091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20080091</ArticleId><ArticleId IdType="pmc">PMC2442638</ArticleId><ArticleId IdType="pubmed">18591409</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Langereis M.A., van Kuppeveld F.J. Induction and suppression of innate antiviral responses by picornaviruses. Cytokine Growth Factor Rev. 2014;25:577&#x2013;585. doi: 10.1016/j.cytogfr.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC7172595</ArticleId><ArticleId IdType="pubmed">25086453</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau D.H., Yuan J., Zhang H., Cheung P., Lim T., Liu Z., Sall A., Yang D. Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. Apoptosis. 2007;12:513&#x2013;524. doi: 10.1007/s10495-006-0013-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-006-0013-0</ArticleId><ArticleId IdType="pubmed">17195095</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S., Wang Y., Lin L., Si X., Wang T., Zhong X., Tong L., Luan Y., Chen Y., Li X., et al. Protease 2A induces stress granule formation during coxsackievirus B3 and enterovirus 71 infections. Virol. J. 2014;11:192. doi: 10.1186/s12985-014-0192-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-014-0192-1</ArticleId><ArticleId IdType="pmc">PMC4247557</ArticleId><ArticleId IdType="pubmed">25410318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.M., Song W.Q., Li Y.J., Qian J., Zhai A.X., Wu J., Li A.M., He J.M., Zhao J.Y., Yu X., et al. Over-expression of mitochondrial antiviral signaling protein inhibits coxsackievirus B3 infection by enhancing type-I interferons production. Virol. J. 2012;9:312. doi: 10.1186/1743-422X-9-312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-312</ArticleId><ArticleId IdType="pmc">PMC3546859</ArticleId><ArticleId IdType="pubmed">23249700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A., Morosky S.A., Delorme-Axford E., Dybdahl-Sissoko N., Oberste M.S., Wang T., Coyne C.B. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog. 2011;7:e1001311. doi: 10.1371/journal.ppat.1001311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001311</ArticleId><ArticleId IdType="pmc">PMC3059221</ArticleId><ArticleId IdType="pubmed">21436888</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller O., Kochs G. Human MxA protein: An interferon-induced dynamin-like GTPase with broad antiviral activity. J. Interferon Cytokine Res. 2011;31:79&#x2013;87. doi: 10.1089/jir.2010.0076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2010.0076</ArticleId><ArticleId IdType="pubmed">21166595</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahnefeld A., Klingel K., Schuermann A., Diny N.L., Althof N., Lindner A., Bleienheuft P., Savvatis K., Respondek D., Opitz E., et al. Ubiquitin-like protein ISG15 (interferon-stimulated gene of 15 kDa) in host defense against heart failure in a mouse model of virus-induced cardiomyopathy. Circulation. 2014;130:1589&#x2013;1600. doi: 10.1161/CIRCULATIONAHA.114.009847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.009847</ArticleId><ArticleId IdType="pubmed">25165091</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstrom-Tullberg M., Hultcrantz M., Stotland A., Maday A., Tsai D., Fine C., Williams B., Silverman R., Sarvetnick N. RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J. Immunol. 2005;174:1171&#x2013;1177. doi: 10.4049/jimmunol.174.3.1171.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.3.1171</ArticleId><ArticleId IdType="pubmed">15661870</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstrom M., Horwitz M.S., Maday A., Balakrishna D., Rodriguez E., Sarvetnick N. A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection. Virology. 2001;281:205&#x2013;215. doi: 10.1006/viro.2000.0801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0801</ArticleId><ArticleId IdType="pubmed">11277693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenstein C.J., Hill S.L., Lafond-Walker A., Wu J., Allen G., Landavere M., Rose N.R., Herskowitz A. Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Investig. 1996;97:1837&#x2013;1843. doi: 10.1172/JCI118613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118613</ArticleId><ArticleId IdType="pmc">PMC507251</ArticleId><ArticleId IdType="pubmed">8621766</ArticleId></ArticleIdList></Reference><Reference><Citation>Broquet A.H., Hirata Y., McAllister C.S., Kagnoff M.F. RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium. J. Immunol. 2011;186:1618&#x2013;1626. doi: 10.4049/jimmunol.1002862.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002862</ArticleId><ArticleId IdType="pubmed">21187438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pott J., Mahlakoiv T., Mordstein M., Duerr C.U., Michiels T., Stockinger S., Staeheli P., Hornef M.W. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA. 2011;108:7944&#x2013;7949. doi: 10.1073/pnas.1100552108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1100552108</ArticleId><ArticleId IdType="pmc">PMC3093475</ArticleId><ArticleId IdType="pubmed">21518880</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldridge M.T., Nice T.J., McCune B.T., Yokoyama C.C., Kambal A., Wheadon M., Diamond M.S., Ivanova Y., Artyomov M., Virgin H.W. Commensal microbes and interferon-lambda determine persistence of enteric murine norovirus infection. Science. 2015;347:266&#x2013;269. doi: 10.1126/science.1258025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1258025</ArticleId><ArticleId IdType="pmc">PMC4409937</ArticleId><ArticleId IdType="pubmed">25431490</ArticleId></ArticleIdList></Reference><Reference><Citation>Nice T.J., Baldridge M.T., McCune B.T., Norman J.M., Lazear H.M., Artyomov M., Diamond M.S., Virgin H.W. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015;347:269&#x2013;273. doi: 10.1126/science.1258100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1258100</ArticleId><ArticleId IdType="pmc">PMC4398891</ArticleId><ArticleId IdType="pubmed">25431489</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanifer M.L., Kee C., Cortese M., Zumaran C.M., Triana S., Mukenhirn M., Kraeusslich H.G., Alexandrov T., Bartenschlager R., Boulant S. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells. Cell Rep. 2020;32:107863. doi: 10.1016/j.celrep.2020.107863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107863</ArticleId><ArticleId IdType="pmc">PMC7303637</ArticleId><ArticleId IdType="pubmed">32610043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlakoiv T., Hernandez P., Gronke K., Diefenbach A., Staeheli P. Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015;11:e1004782. doi: 10.1371/journal.ppat.1004782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004782</ArticleId><ArticleId IdType="pmc">PMC4388470</ArticleId><ArticleId IdType="pubmed">25849543</ArticleId></ArticleIdList></Reference><Reference><Citation>Alidjinou E.K., Sane F., Engelmann I., Geenen V., Hober D. Enterovirus persistence as a mechanism in the pathogenesis of type 1 diabetes. Discov. Med. 2014;18:273&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">25425468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K., Lynch K.F., Wong M.C., Tian X., Ross M.C., Gibbs R.A., Ajami N.J., Petrosino J.F., Rewers M., Toppari J., et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat. Med. 2019;25:1865&#x2013;1872. doi: 10.1038/s41591-019-0667-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pmc">PMC6898786</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata Y., Broquet A.H., Menchen L., Kagnoff M.F. Activation of innate immune defense mechanisms by signaling through RIG-I/IPS-1 in intestinal epithelial cells. J. Immunol. 2007;179:5425&#x2013;5432. doi: 10.4049/jimmunol.179.8.5425.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.8.5425</ArticleId><ArticleId IdType="pubmed">17911629</ArticleId></ArticleIdList></Reference><Reference><Citation>Su R., Shereen M.A., Zeng X., Liang Y., Li W., Ruan Z., Li Y., Liu W., Liu Y., Wu K., et al. The TLR3/IRF1/Type III IFN Axis Facilitates Antiviral Responses against Enterovirus Infections in the Intestine. mBio. 2020;11 doi: 10.1128/mBio.02540-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02540-20</ArticleId><ArticleId IdType="pmc">PMC7683398</ArticleId><ArticleId IdType="pubmed">33203755</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>